{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T04:26:39Z","timestamp":1748492799137,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s11255-019-02175-5","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T04:02:11Z","timestamp":1559534531000},"page":"1261-1270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of secondary hyperparathyroidism with paricalcitol in patients with end-stage renal disease undergoing hemodialysis in Turkey: an observational study"],"prefix":"10.1007","volume":"51","author":[{"given":"Hasan","family":"Koc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Hoser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalcin","family":"Akdag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cemaliye","family":"Kendir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9722-1560","authenticated-orcid":false,"given":"F. Fevzi","family":"Ersoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,3]]},"reference":[{"issue":"Suppl. 9","key":"2175_CR1","first-page":"19","volume":"22","author":"C Daly","year":"2007","unstructured":"Daly C (2007) Is early chronic kidney disease an important risk factor for cardiovascular disease A background paper prepared for the UK consensus conference on early chronic kidney disease. Nephrol Dial Transplant 22(Suppl. 9):19\u201325","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"2175_CR2","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/00000441-200603000-00007","volume":"331","author":"MA Perazella","year":"2006","unstructured":"Perazella MA, Khan S (2006) Increased mortality in chronic kidney disease: a call to action. Am J Med Sci 331(3):150\u2013153","journal-title":"Am J Med Sci"},{"issue":"7","key":"2175_CR3","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1681\/ASN.2005101085","volume":"17","author":"M Tonelli","year":"2006","unstructured":"Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX (2006) Chronic kidney disease\u00a0and mortality\u00a0risk: a systematic review. J Am Soc Nephrol 17(7):2034\u20132047 (Epub 2006 May 31)","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2175_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1742-1241.2012.02954.x","volume":"67","author":"R Hajhosseiny","year":"2013","unstructured":"Hajhosseiny R, Khavandi K, Goldsmith DJ (2013) Cardiovascular disease in chronic kidney disease: untying the Gordian knot. Int J Clin Pract 67(1):14\u201331","journal-title":"Int J Clin Pract"},{"issue":"Suppl 3","key":"2175_CR5","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","volume":"32","author":"RN Foley","year":"1998","unstructured":"Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32(Suppl 3):S112\u2013S119","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2175_CR6","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/nu5031002","volume":"5","author":"M Abe","year":"2013","unstructured":"Abe M, Okada K, Soma M (2013) Mineral metabolic abnormalities and mortality in dialysis patients. Nutrients. 5(3):1002\u20131023. \n                    https:\/\/doi.org\/10.3390\/nu5031002","journal-title":"Nutrients."},{"key":"2175_CR7","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208\u20132218","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2175_CR8","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4103\/2230-8210.93749","volume":"16","author":"B Bansal","year":"2012","unstructured":"Bansal B, Bansal S, Mithal A, Kher V, Marwaha R (2012) Vitamin D deficiency in hemodialysis patients. Indian J Endocrinol Metab 16(2):270\u2013273. \n                    https:\/\/doi.org\/10.4103\/2230-8210.93749","journal-title":"Indian J Endocrinol Metab"},{"key":"2175_CR9","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1681\/ASN.2004040275","volume":"16","author":"Y Slinin","year":"2005","unstructured":"Slinin Y, Foley RN, Collins AJ (2005) Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 16:1788\u20131793","journal-title":"J Am Soc Nephrol"},{"key":"2175_CR10","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1093\/eurheartj\/ehq246","volume":"31","author":"C Drechsler","year":"2010","unstructured":"Drechsler C, Pilz S, Obermayer-Pietsch B, Verduijn M, Tomaschitz A, Krane V et al (2010) Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 31:2253\u20132261","journal-title":"Eur Heart J"},{"key":"2175_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1681\/ASN.2004070602","volume":"16","author":"B Kestenbaum","year":"2005","unstructured":"Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B et al (2005) Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16:520\u2013528","journal-title":"J Am Soc Nephrol"},{"key":"2175_CR12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s10157-012-0626-2","volume":"16","author":"T Ogawa","year":"2012","unstructured":"Ogawa T, Kyono A, Sato M, Sugimoto H, Otsuka K, Nitta K (2012) Vitamin D receptor agonist supplementation and suppression of inflammation may have advantage for all-cause mortality in hemodialysis patients. Clin Exp Nephrol 16:779\u2013785","journal-title":"Clin Exp Nephrol"},{"issue":"8","key":"2175_CR13","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","volume":"27","author":"M Ketteler","year":"2012","unstructured":"Ketteler M, Martin KJ, Wolf M, Amdahl M, Cozzolino M, Goldsmith D, Sharma A, Marx S, Khan S (2012) Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant 27(8):3270\u20133278","journal-title":"Nephrol Dial Transplant"},{"key":"2175_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000325454","volume":"32","author":"D Brancaccio","year":"2011","unstructured":"Brancaccio D, Cozzolino M, Cannella G, Messa P, Bonomini M, Cancarini G et al (2011) Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality. Blood Purif 32:124\u2013132","journal-title":"Blood Purif"},{"key":"2175_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12882-015-0006-8","volume":"16","author":"P Messa","year":"2015","unstructured":"Messa P, Cozzolino M, Brancaccio D, on behalf of the FARO Study Group et al (2015) Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study. BMC Nephrol 16:11","journal-title":"BMC Nephrol"},{"key":"2175_CR16","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/ndt\/gfn492","volume":"24","author":"MG Vervloet","year":"2009","unstructured":"Vervloet MG, Twisk JWR (2009) Mortality reduction by vitamin D receptor activation in end-stage renal disease: a commentary on the robustness of current data. Nephrol Dial Transplant 24:703\u2013706. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfn492","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 1","key":"2175_CR17","first-page":"S1","volume":"39","author":"National Kidney Foundation","year":"2002","unstructured":"National Kidney Foundation (2002) K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 39(suppl 1):S1\u2013S266","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"2175_CR18","first-page":"1","volume":"2017","author":"KDIGO","year":"2017","unstructured":"KDIGO (2017) Clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2017(7):1\u201359","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"2175_CR19","doi-asserted-by":"publisher","first-page":"302","DOI":"10.5935\/0101-2800.20160047","volume":"38","author":"I Olaizola","year":"2016","unstructured":"Olaizola I, Caorsi H, Fajardo L, Ferreiro A, Campistrus N, Dolinsky D, Petraglia A, Ambrosoni P (2016) Effectiveness and safety of a 6-month treatment with paricalcitol in patients on hemodialysis with secondary hyperparathyroidism. J Bras Nefrol 38(3):302\u2013312","journal-title":"J Bras Nefrol"},{"key":"2175_CR20","doi-asserted-by":"publisher","first-page":"S300","DOI":"10.1097\/01.ASN.0000081663.52165.66","volume":"14","author":"CM Giachelli","year":"2003","unstructured":"Giachelli CM (2003) Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 14:S300\u2013S304","journal-title":"J Am Soc Nephrol"},{"key":"2175_CR21","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1097\/01.ASN.0000145894.57533.C4","volume":"15","author":"CM Giachelli","year":"2004","unstructured":"Giachelli CM (2004) Vascular calcification mechanisms. J Am Soc Nephrol 15:2959\u20132964","journal-title":"J Am Soc Nephrol"},{"key":"2175_CR22","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1681\/ASN.2006121385","volume":"18","author":"JR Stubbs","year":"2007","unstructured":"Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X et al (2007) Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 18:2116\u20132124","journal-title":"J Am Soc Nephrol"},{"key":"2175_CR23","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1093\/ndt\/gfs050","volume":"27","author":"J Silver","year":"2012","unstructured":"Silver J, Rodriguez M, Slatopolsky E (2012) FGF23 and PTH-double agents at the heart of CKD. Nephrol Dial Transplant 27:1715\u20131720","journal-title":"Nephrol Dial Transplant"},{"key":"2175_CR24","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1053\/ajkd.2001.28114","volume":"38","author":"F Llach","year":"2001","unstructured":"Llach F, Yudd M (2001) Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 38:S45\u2013S50","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"2175_CR25","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1093\/ndt\/gft227","volume":"28","author":"DW Coyne","year":"2013","unstructured":"Coyne DW, Andress DL, Amdahl MJ, Ritz E, de Zeeuw D (2013) Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study. Nephrol Dial Transplant 28(9):2260\u20132268","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"2175_CR26","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2215\/CJN.10661013","volume":"9","author":"DW Coyne","year":"2014","unstructured":"Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM (2014) A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol 9(9):1620\u20131626","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"2175_CR27","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1681\/ASN.2008010014","volume":"19","author":"DL Regidor","year":"2008","unstructured":"Regidor DL, Kovesdy CP, Mehrotra R et al (2008) Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 19(11):2193\u20132203","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2175_CR28","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1056\/NEJMoa022536","volume":"349","author":"M Teng","year":"2003","unstructured":"Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349(5):446\u2013456","journal-title":"N Engl J Med"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02175-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-019-02175-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02175-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:35:13Z","timestamp":1591058113000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-019-02175-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,3]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["2175"],"URL":"https:\/\/doi.org\/10.1007\/s11255-019-02175-5","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"type":"print","value":"0301-1623"},{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2019,6,3]]},"assertion":[{"value":"25 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was sponsored by AbbVie. AbbVie contributed to the study design, research, and interpretation of data, writing, reviewing, and approving the publication. The design, study conduct, and financial support for the Zemplar PMOS study (protocol number P12-314) were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication. All authors received payments from AbbVie to participate in this study. In addition, F. Fevzi Ersoy has received speaker and\/or consultancy fees from AbbVie, Sanofi, Abdi Ibrahim and Roche. Hasan Hoser, Hasan Koc, Yalcin Akdag and Cemaliye Kendir have not received speaker and\/or consultancy fees from AbbVie or any other pharmaceutical companies. The authors would like to acknowledge the other participants of the P12-314 Study Team.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}